TBPH · CIK 0001583107
What Theravance Biopharma, Inc. told the SEC could break it.
Theravance's disclosures describe a company riding almost entirely on a single drug, YUPELRI. Every link in that product's chain is single-threaded — one supplier of its active ingredient, one of finished drug product, and a single warehouse — and its revenue is just as concentrated: the Viatris collaboration that commercializes YUPELRI was 100% of total revenue ($75.0 million) in 2025. Its main bid to broaden beyond YUPELRI faltered when the CYPRESS trial of ampreloxetine missed its primary endpoint in March 2026, prompting a restructuring, even as YUPELRI's Medicare reimbursement leaves it exposed to IRA drug-pricing changes, including a new 10% Part D manufacturer discount.
4 self-disclosed vulnerabilities, pulled from its own filings — each in the company’s words, with the source. This is the risk register almost nobody reads.
In its own words
What could break it.
Sole-source dependency
- single-source YUPELRI API, drug product & warehousehigh
YUPELRI's supply chain is entirely single-threaded — one supplier of API, one supplier of drug product, and a single warehousing facility — so any disruption could harm Theravance's business with no ready alternative.
“There is a single supplier of YUPELRI API, a single supplier of YUPELRI drug product and YUPELRI is warehoused in a single facility.”
SEC filing →As of 2026
Customer concentration
- Viatris = 100% of total revenuemedium
Theravance's revenue comes essentially entirely from its Viatris collaboration (Viatris was 100% of total revenue in 2025 and 2024) — $75.0M in 2025 — so the relationship and YUPELRI's commercial performance fully determine its top line.
“In 2025 and 2024, we recognized $75.0 million and $64.4 million, respectively, in revenue from the Viatris collaboration agreement, which represented an increase of 16%.”
SEC filing →As of 2026
Other disclosures
- ampreloxetine CYPRESS trial failure / pipeline reliancemedium
Theravance's pipeline beyond YUPELRI suffered a setback — the CYPRESS study of ampreloxetine missed its primary endpoint (announced March 3, 2026), undermining a key royalty-backed asset and prompting a March 2026 organizational restructuring.
“On March 3, 2026, we announced that the CYPRESS study did not meet its primary endpoint in the OHSA composite score.”
SEC filing →As of 2026
Regulatory & policy
- IRA Medicare drug-pricing (Part D manufacturer discount)medium
YUPELRI is reimbursed under Medicare, exposing Theravance/Viatris to IRA drug-pricing changes — the sunset of the coverage-gap discount program (2025) and a new manufacturer discount program requiring a 10% Part D discount in the initial coverage phase.
“A new manufacturer discount program replaced the previous program, requiring manufacturers to provide a 10% discount on a covered Part D drug where a beneficiary is in the initial phase of Part D coverage”
The hidden graph
Who it depends on, and who depends on it.
Relationships surfaced from filings — including ones disclosed by the other side, which is how the non-obvious ones come to light.
Its customers
“In the US, Viatris is leading the commercialization of YUPELRI, and we co-promote the product under a profit and loss sharing arrangement (65% to Viatris; 35% to us).”
Cited →
In the MyPRIA app, this is checked against the companies you actually own.
← World Watch